Caribou Biosciences, Inc. (CRBU): restructuring charge — Caribou discontinues CAR-NK platform, cuts 12% workforce to extend cash runway into H2 2026

Caribou Biosciences, Inc.

Preliminary cash $311.8M at June 30, 2024; expects to report Q2 results later.
Discontinues allogeneic CAR-NK preclinical research; focuses on CAR-T cell therapy and four clinical programs.
Workforce reduction of 21 positions (~12%); expects to complete by end of Q3 2024.
Estimated severance costs $0.5M–$1.0M in Q3 2024.
Cash runway extended at least 6 months into H2 2026.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Caribou Biosciences, Inc. announced a restructuring with charges of approximately $0.5 million to $1.0 million affecting allogeneic CAR-NK platform (21 positions, or approximately 12%).

Type: restructuring
Charge: approximately $0.5 million to $1.0 million
Affected area: allogeneic CAR-NK platform
Headcount: 21 positions, or approximately 12%

Exact text from the filing

in cash, cash equivalents, and marketable securities as of June 30, 2024. In connection with the workforce reduction, the Company currently estimates it will incur approximately $0.5 million to $1.0 million in costs, consisting primarily of cash severance costs, benefits, and transition support services for impacted employees, which the Company expects to recognize

View on SEC.gov

Browse all restructurings & charges →

Caribou Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001619856-24-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.